Congenital lipodystrophies and dyslipidemia

Current Atherosclerosis Reports

Volumn 16, Issue 9, 2014, Pages

  Prieur, Xavier ^a,b   Le May, Cedric ^a   Magré, Jocelyne ^a   Cariou, Bertrand ^a,b,c  

^a L INSTITUT DU THORAX   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

BSCL2 seipin; Caveolin 1; Hypertriglyceridemia; Insulin resistance; Lipodystrophy

Indexed keywords

ADIPOSE TISSUE; ANIMAL; COMPLICATION; DYSLIPIDEMIAS; GENETIC PREDISPOSITION; GENETICS; HUMAN; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; METABOLISM; MUTATION;

ADIPOSE TISSUE; ANIMALS; DYSLIPIDEMIAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MUTATION;

EID: 84904447474     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0437-x     Document Type: Review

References (107)

1. •• Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313-25. This is a very comprehensive review in terms of clinical classification of the different lipodystrophic syndromes.
2. Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol. 2010;207:245-55.
3. Vatier C, Bidault G, Briand N, Guénantin AC, Teyssières L, Lascols O, et al. What the genetics of lipodystrophy can teach us about insulin resistance and diabetes. Curr Diabetes Rep. 2013;13:757-67.
4. Vantyghem MC, Balavoine AS, Douillard C, Defrance F, Dieudonne L, Mouton F, et al. How to diagnose a lipodystrophy syndrome. Ann Endocrinol (Paris). 2012;73:170-89.
5. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl. 1996;413:2-28. (Pubitemid 26189575)
6. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87:2395-8. (Pubitemid 34521536)
7. Antuna-Puente B, Boutet E, Vigouroux C, Lascols O, Slama L, Caron-Debarle M, et al. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3- phosphate-O-acyltransferase-2 deficiency. J Clin Endocrinol Metab. 2010;95:1463-8.
8. Garg A, Wilson R, Barnes R, Arioglu E, Zaidi Z, Gurakan F, et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab. 1999;84:3390-4. (Pubitemid 30646973)
9. Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, et al. AGPAT2 ismutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet. 2002;31:21-3.
10. Magré J, Delépine M, Khallouf E, Gedde-Dahl TJ, Van Maldergem L, Sobel E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28:365-70. (Pubitemid 32702427)
11. Magré J, Delépine M, Van Maldergem L, Robert JJ, Maassen JA, Meier M, et al. Prevalence ofmutations in AGPAT2 among human lipodystrophies. Diabetes. 2003;52:1573-8. (Pubitemid 36666217)
12. Kim CA, Delépine M, Boutet E, El Mourabit H, Le Lay S, Meier M, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93:1129-34. (Pubitemid 351540679)
13. Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new formof congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 2010;6(3):e1000874.
14. Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest. 2009;119:2623-33.
15. Knebel B, Kotzka J, Lehr S, Hartwig S, Avci H, Jacob S, et al. A mutation in the c-fos gene associated with congenital generalized lipodystrophy. Orphanet J Rare Dis. 2013;8:119.
16. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-34. (Pubitemid 38339366)
17. Peters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet. 1998;18:292-5.
18. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet. 2000;24:153-6. (Pubitemid 30094715)
19. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000;9:109-12. (Pubitemid 30145295)
20. Speckman RA, Garg A, Du F, Bennett L, Veile R, Arioglu E, et al. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. Am J Hum Genet. 2000;66:1192-8. (Pubitemid 30468776)
21. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-3.
22. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304:1325-8. (Pubitemid 38697429)
23. Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1:280-7.
24. Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med. 2011;364:740-8.
25. Van Maldergem L, Magré J, Gedde-DahlJr T, Khallouf E, Delépine M, Trygstad O, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002;39:722-33. (Pubitemid 35178722)
26. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-65. (Pubitemid 43357551)
27. Beylot M, Sautot G, Laville M, Cohen R. Metabolic studies in lipoatrophic diabetes: mechanism of hyperglycemia and evidence of resistance to insulin of lipid metabolism. Diabete Metab. 1988;14:20-4.
28. Wajchenberg BL, Amâncio RF, Santomauro AT, Maranhão RC. Metabolism of chylomicrons in patients with congenital lipoatrophic diabetes: a study with emulsion models of chylomicrons. Clin Endocrinol (Oxf). 2004;61:347-52. (Pubitemid 39287064)
29. Kodama S, Kasuga M, Seki A, Ninomiya M, Sakurai T, Morishita Y, et al. Congenital generalized lipodystrophy with insulin-resistant diabetes. Eur J Pediatr. 1978;127:111-9. (Pubitemid 8260715)
30. Naito C, Togawa K. A possible role of circulating lipoproteintriglycerides in the increase in concentration of free fatty acids and in insulin resistance in "total" lipodystrophy. J Clin Endocrinol Metab. 1974;39:1030-7.
31. Enzi G, Digito M, Baldo-Enzi G, Cominacini L, Dodi G, Carraro R, et al. Lipid metabolism in lipoatrophic diabetes. Horm Metab Res. 1988;20:587-91.
32. Tan GD, Savage DB, Fielding BA, Collins J, Hodson L, Humphreys SM, et al. Fatty acid metabolism in patients with PPARγ mutations. J Clin Endocrinol Metab. 2008;93:4462-70. (Pubitemid 352789548)
33. Savage DB, Murgatroyd PR, Chatterjee VK, O'Rahilly S. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J Clin Endocrinol Metab. 2005;90:1446-52. (Pubitemid 40464002)
34. Savage DB, Semple RK, Clatworthy MR, Lyons PA, Morgan BP, Cochran EK, et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2009;94:10-6.
35. Ross R, Graves A, Spiegelman M. Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity. Genes Dev. 1993;7:1318-24.
36. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12:3182-94. (Pubitemid 28496263)
37. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al. Life without white fat: a transgenic mouse. Genes Dev. 1998;12:3168-81. (Pubitemid 28496262)
38. Linhart HG, Ishimura-Oka K, DeMayo F, Kibe T, Repka D, Poindexter B, et al. C/EBPα is required for differentiation of white, but not brown, adipose tissue. Proc Natl Acad Sci U S A. 2001;98:12532-7. (Pubitemid 33019980)
39. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105:271-8. (Pubitemid 30094446)
40. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73-6.
41. Ebihara K, Ogawa Y, Masuzaki H, Shintani M, Miyanaga F, Aizawa-Abe M, et al. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes. 2001;50:1440-8. (Pubitemid 32500178)
42. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4:611-7. (Pubitemid 29531140)
43. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585-95. (Pubitemid 29531138)
44. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, et al. Adiposespecific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A. 2003;100:15712-7. (Pubitemid 38021055)
45. • Wang F, Mullican SE, DiSpirito JR, Peed LC, Lazar MA. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ. Proc Natl Acad Sci U S A. 2013;110:18656-61. Complete deletion of PPARγ in mature adipocytes has been quite a challenge during the last 10 years. This article provides important insight into the role of PPARγ after the initiation of adipogenesis.
46. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem. 2002;277:8635-47. (Pubitemid 34968330)
47. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68:673-82.
48. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. 2003;285:C222-35. (Pubitemid 36736354)
49. Le Lay S, Blouin CM, Hajduch E, Dugail I. Filling up adipocytes with lipids. Lessons from caveolin-1 deficiency. Biochim Biophys Acta. 2009;1791:514-8.
50. Le Lay S, Hajduch E, Lindsay MR, Le Liepvre X, Thiele C, Ferre P, et al. Cholesterol-induced caveolin targeting to lipid droplets in adipocytes: a role for caveolar endocytosis. Traffic. 2006;7:549-61. (Pubitemid 44026753)
51. Blouin CM, Le Lay S, Eberl A, Kofeler HC, Guerrera IC, Klein C, et al. Lipid droplet analysis in caveolin-deficient adipocytes: alterations in surface phospholipid composition and maturation defects. J Lipid Res. 2010;51:945-56.
52. Le Lay S, Briand N, Blouin CM, Chateau D, Prado C, Lasnier F, et al. The lipoatrophic caveolin-1 deficient mouse model reveals autophagy in mature adipocytes. Autophagy. 2010;6:754-63.
53. Martin S, Fernandez-Rojo MA, Stanley AC, Bastiani M, Okano S, Nixon SJ, et al. Caveolin-1 deficiency leads to increased susceptibility to cell death and fibrosis in white adipose tissue: characterization of a lipodystrophic model. PLoS One. 2012;7:e46242.
54. Frank PG, Lee H, Park DS, Tandon NN, Scherer PE, Lisanti MP. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:98-105. (Pubitemid 38082418)
55. Cortés VA, Curtis DE, Sukumaran S, Shao X, Parameswara V, Rashid S, et al. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab. 2009;9:165-76.
56. -/- gene lipodystrophic mice. J Biol Chem. 2011;286:37676-91. In this study, the authors demontrate that liver re-expression of AGPAT2 is not sufficient to rescue the severe liver steatosis phenotype.
57. Subauste AR, Das AK, Li X, Elliott BG, Elliot B, Evans C, et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes. 2012;61:2922-31.
58. Gale SE, Frolov A, Han X, Bickel PE, Cao L, Bowcock A, et al. A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation. J Biol Chem. 2006;281:11082-9. (Pubitemid 43855532)
59. Reue K, Xu P, Wang XP, Slavin BG. Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene. J Lipid Res. 2000;41:1067-76. (Pubitemid 30483010)
60. Langner CA, Birkenmeier EH, Ben-Zeev O, Schotz MC, Sweet HO, Davisson MT, et al. The fatty liver dystrophy (fld) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities. J Biol Chem. 1989;264:7994-8003. (Pubitemid 19137280)
61. Donkor J, Sariahmetoglu M, Dewald J, Brindley DN, Reue K. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J Biol Chem. 2007;282:3450-7. (Pubitemid 47084457)
62. Phan J, Péterfy M, Reue K. Lipin expression preceding peroxisome proliferator-activated receptor-γ is critical for adipogenesis in vivo and in vitro. J Biol Chem. 2004;279:29558-64. (Pubitemid 38915837)
63. • Nadra K, Médard JJ, Mul JD, Han GS, Grès S, Pende M, et al. Cell autonomous lipin 1 function is essential for development and maintenance of white and brown adipose tissue. Mol Cell Biol. 2012;32:4794-810. In this study, the authors demonstrate for the first time that adipocyte-specific deletion of lipin 1 is responsible for the lipodystrophic phenotype in Fld mice. This is a very complete invivo and invitro study.
64. Chen Z, Gropler MC, Norris J, Lawrence JC, Harris TE, Finck BN. Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion. Arterioscler Thromb Vasc Biol. 2008;28:1738-44.
65. Hu M, Yin H, Mitra MS, Liang X, Ajmo JM, Nadra K, et al. Hepatic-specific lipin-1 deficiency exacerbates experimental alcohol-induced steatohepatitis in mice. Hepatology. 2013;58:1953-63.
66. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116:615-22. (Pubitemid 43326866)
67. Fei W, Shui G, Gaeta B, Du X, Kuerschner L, Li P, et al. Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J Cell Biol. 2008;180:473-82. (Pubitemid 351240697)
68. Szymanski KM, Binns D, Bartz R, Grishin NV, Li WP, Agarwal AK, et al. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc Natl Acad Sci U S A. 2007;104:20890-5.
69. Boutet E, El Mourabit H, Prot M, Nemani M, Khallouf E, Colard O, et al. Seipin deficiency alters fatty acid Δ9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy. Biochimie. 2009;91:796-803.
70. Cartwright BR, Goodman JM. Seipin: from human disease to molecular mechanism. J Lipid Res. 2012;53:1042-55.
71. Payne VA, Grimsey N, Tuthill A, Virtue S, Gray SL, DallaNora E, et al. The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes. 2008;57:2055-60.
72. Chen W, Yechoor VK, Chang BH, Li MV, March KL, Chan L. The human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2/seipin plays a key role in adipocyte differentiation. Endocrinology. 2009;150:4552-61.
73. Chen W, Chang B, Saha P, Hartig SM, Li L, Reddy VT, et al. Berardinelli-Seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation. Mol Cell Biol. 2012;32:1099-111.
74. Prieur X, Dollet L, Takahashi M, Nemani M, Pillot B, Le May C, et al. Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. Diabetologia. 2013;56:1813-25.
75. Cui X, Wang Y, Tang Y, Liu Y, Zhao L, Deng J, et al. Seipin ablation in mice results in severe generalized lipodystrophy. Hum Mol Genet. 2011;20:3022-30.
76. Dollet L, Magré J, Cariou B, Prieur X. Function of seipin: new insights from Bscl2/seipin knockout mouse models. Biochimie. 2014;96:166-72.
77. Liu L, Jiang Q, Wang X, Zhang Y, Lin RC, Lam SM, et al. Adipose-specific knockout of Seipin/Bscl2 results in progressive lipodystrophy. Diabetes. 2014. doi:10.2337/db13-0729.
78. Fei W, Shui G, Zhang Y, Krahmer N, Ferguson C, Kapterian TS, et al. A role for phosphatidic acid in the formation of "supersized" lipid droplets. PLoS Genet. 2011;7:e1002201.
79. Sim MF, Dennis RJ, Aubry EM, Ramanathan N, Sembongi H, Saudek V, et al. The human lipodystrophy protein seipin is an ER membrane adaptor for the adipogenic PA phosphatase lipin 1. Mol Metab. 2012;2:38-46.
80. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 2003;82:129-46. (Pubitemid 36331644)
81. Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19:107-16.
82. Tsiodras S, Poulia KA, Yannakoulia M, Chimienti SN, Wadhwa S, Karchmer AW, et al. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism. 2009;58:854-9.
83. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309-18.
84. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
85. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.
86. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
87. Johns KW, Bennett MT, Bondy GP. Are HIV positive patients resistant to statin therapy? Lipids Health Dis. 2007;6:27.
88. Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infectedmen-a randomized, placebo-controlled study. AIDS. 2006;20:1003-10.
89. Viollet B, Guigas B, SanzGarcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253-70.
90. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010;10:183.
91. van Wijk JP, Hoepelman AI, de Koning EJ, Dallinga-Thie G, Rabelink TJ, Cabezas MC. Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arterioscler Thromb Vasc Biol. 2011;31:228-33.
92. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205-15.
93. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169-76. (Pubitemid 38970772)
94. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-91. (Pubitemid 34655345)
95. Juurinen L, Kotronen A, Granér M, Yki-Järvinen H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab. 2008;93:118-24.
96. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133:263-74. (Pubitemid 30660298)
97. Lüdtke A, Heck K, Genschel J, Mehnert H, Spuler S, Worman HJ, et al. Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone. Diabet Med. 2005;22:1611-3. (Pubitemid 41641172)
98. Gambineri A, Semple RK, Forlani G, Genghini S, Grassi I, Hyden CS, et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol. 2008;159:347-53.
99. Moreau F, Boullu-Sanchis S, Vigouroux C, Lucescu C, Lascols O, Sapin R, et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 2007;33:385-9. (Pubitemid 350030908)
100. McLaughlin PD, Ryan J, Hodnett PA, O' Halloran D, Maher MM. Quantitative whole-body MRI in familial partial lipodystrophy type 2: changes in adipose tissue distribution coincide with biochemical improvement. AJR Am J Roentgenol. 2012;199:W602-6.
101. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-307. (Pubitemid 44837778)
102. Simha V, Rao S, Garg A. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety. Diabetes Obes Metab. 2008;10:1275-6.
103. Victoria B, Cabezas-Agricola JM, Gonzalez-Mendez B, Lattanzi G, Del Coco R, Loidi L, et al. Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy. Diabet Med. 2010;27:1178-87.
104. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-54. (Pubitemid 40923063)
105. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89. (Pubitemid 41416583)
106. Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17:922-32.
107. Beltrand J, Lahlou N, Le Charpentier T, Sebag G, Leka S, Polak M, et al. Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol. 2010;162:1083-91.